Topics

Fluocinonide Ointment, 0.05% | Fluocinonide [County Line Pharmaceuticals, LLC] | BioPortfolio

17:46 EST 26th January 2019 | BioPortfolio
Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Rx Only

Fluocinonide Ointment, 0.05% is intended for topical administration. The active component is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna-1,4-diene-3,20-dione,21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(6α,11β,16α)-. It has the following chemical structure:

Fluocinonide Ointment contains fluocinonide 0.5 mg/g in a specially formulated ointment base consisting of glyceryl monostearate, white petrolatum, propylene carbonate, propylene glycol and white wax. It provides the occlusive and emollient effects desirable in an ointment.

In this formulation, the active ingredient is totally in solution.

Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Fluocinonide Ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS – Pediatric Use). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

As with any topical corticosteroid product, prolonged use may produce atrophy of the skin and subcutaneous tissues. When used on intertriginous or flexor areas, or on the face, this may occur even with short-term use.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Patients using topical corticosteroids should receive the following information and instructions:

The following tests may be helpful in evaluating the HPA axis suppression:

Urinary free cortisol test

ACTH stimulation test

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalmic-pituitary-adrenal (HPA) axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

Burning Perioral dermatitis
Itching Allergic contact dermatitis
Irritation Maceration of the skin
Dryness Secondary infection
Folliculitis Skin atrophy
Hypertrichosis Striae
Acneiform eruptions Miliaria
Hypopigmentation

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).

Fluocinonide Ointment is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition.

Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.

If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Fluocinonide Ointment, 0.05% is supplied in 15 g Tube – NDC 43199-029-15 30 g Tube – NDC 43199-029-30 60 g Tube – NDC 43199-029-60

Store at room temperature. Avoid excess heat, above 30°C (86°F)

Manufactured for: County Line Pharmaceuticals, LLC Brookfield, WI 53005 For Inquiries Call: 1-866-770-3024Made in Canada 05/2016

Tube

NDC 43199-029-15

15 Grams

Fluocinonide Ointment, 0.05%

Manufactured for:

County Line Pharmaceuticals, LLC

Brookfield, WI 53005F

Made in Canada

Carton

NDC 43199-029-15

15 Grams

Fluocinonide Ointment, 0.05%

Manufactured for:

County Line Pharmaceuticals, LLC

Brookfield, WI 53005F

Made in Canada

Tube

NDC 43199-029-30

30 Grams

Fluocinonide Ointment, 0.05%

Manufactured for:County Line Pharmaceuticals, LLC

Brookfield, WI 53005F

Made in Canada

Carton

NDC 43199-029-30

30 Grams

Fluocinonide Ointment, 0.05%

Manufactured for:

County Line Pharmaceuticals, LLC

Brookfield, WI 53005F

Made in Canada

Tube

NDC 43199-029-60

60 Grams

Fluocinonide Ointment, 0.05%

Manufactured for:

County Line Pharmaceuticals, LLC

Brookfield, WI 53005F

Made in Canada

Carton

NDC 43199-029-60

60 Grams

Fluocinonide Ointment, 0.05%

Manufactured for:

County Line Pharmaceuticals, LLC

Brookfield, WI 53005F

Made in Canada

Manufacturer

County Line Pharmaceuticals, LLC

Active Ingredients

Source

Drugs and Medications [80 Associated Drugs and Medications listed on BioPortfolio]

Fluocinonide [oceanside pharmaceuticals]

These highlights do not include all the information needed to use Fluocinonide Cream safely and effectively. See full prescribing information for Fluocinonide Cream. Fluocinonide Cream, 0.1%For topica...

Fluocinonide [a-s medication solutions]

Fluocinonide Cream USP, 0.05% Fluocinonide Cream USP, 0.05% (Emulsified Base) Fluocinonide Gel USP, 0.05% Fluocinonide Ointment USP, 0.05%

Fluocinonide [preferred pharmaceuticals, inc.]

Fluocinonide Cream USP, 0.05% Fluocinonide Cream USP, 0.05% (Emulsified Base) Fluocinonide Gel USP, 0.05% Fluocinonide Ointment USP, 0.05%

Fluocinonide [proficient rx lp]

Fluocinonide Cream USP, 0.05% Fluocinonide Cream USP, 0.05% (Emulsified Base) Fluocinonide Gel USP, 0.05% Fluocinonide Ointment USP, 0.05%

Fluocinonide [rebel distributors corp]

Fluocinonide Cream USP, 0.05% Fluocinonide Cream USP, 0.05% (Emulsified Base) Fluocinonide Gel USP, 0.05% Fluocinonide Ointment USP, 0.05%

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis

The purpose of this research study is to better understand how fluocinonide cream 0.1% (Vanos®) works when people use it to treat atopic dermatitis for just a few days.

VANOS Cream and Skin Barrier Function

The purpose of this study is to determine the effect of short-term therapy using "VANOS Cream," a super-potent topical steroid cream on skin barrier function in patients with atopic dermat...

PubMed Articles [0 Results]

None

Quick Search

Relevant Topic

Immunoassay - ELISA
Immunoassays are quick and accurate tests to detect specific molecules. Immunoassays rely on an antibody to bind to the specific structure of a molecule. Antibodies are proteins generated by animals in response to the invasion of a foreign molecule (anti...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record